November 2026: Russia Justifies Temporary Control of Japan Tobacco’s Assets The Russian government has defended its decision to place Japan Tobacco (JT) Russian assets under temporary administration, describing the measure as a response to Japan’s economic sanctions against Russia following its invasion of Ukraine. Speaking at a press conference, the

Earnings Forecasts Raised as Pricing and Ploom Growth Support Performance Japan Tobacco (JT) delivered another quarter of solid financial growth, supported by resilient combustible pricing, continued market share gains, and accelerating momentum in Heated Products (Ploom). For the first nine months of 2026, consolidated revenue increased 13.6% year over year,

Ahead of the Q2 2026 Earnings release Date: July 30, 2026 (Thursday), After Market Close Consensus Estimates: ¥986.2 billion Revenue (+8.7% yoy); ¥97.6 EPS (+6.6% yoy) Guidance: JT’s FY26 guidance targets +6.6% revenue (+3.6% core tobacco revenue at constant FX), +7.9% adjusted operating profit (+8.9% at constant FX) and +14.2% basic EPS growth

July 2026: JT Expands Processed Food Operations and Business Development Pipeline Japan Tobacco (JT) is expanding its non-tobacco capabilities, positioning its processed food segment as a complementary growth driver alongside its core tobacco and reduced-risk product operations. JT’s processed food segment operates primarily through its subsidiary TableMark, alongside Fuji Foods

Japan Tobacco reported a strong start to FY2026, with broad-based growth across the tobacco business, continued pricing power in combustibles, accelerating reduced-risk product (RRP) momentum, and substantial earnings leverage aided by favorable foreign exchange movements. Management maintained its full-year outlook and emphasized that investments behind Ploom AURA and broader RRP

April 2026: S&P Downgrades Japan Tobacco to “A” on Geopolitical Risk Exposure, Maintains Stable Outlook S&P Global has lowered its long-term issuer credit rating on Japan Tobacco (JT) to “A” from “A+”, while affirming its short-term issuer credit rating at “A-1”. The stable outlook reflects the view that JT will

Consolidated Results FY25 Revenue up +13.4% to ¥3,467.7 billion (+13.9% at constant FX); Adjusted operating profit up +21.5% to ¥902.2 billion (+24.9% at constant FX) Tobacco Segment: 91.8% weight in revenue, 100+% weight in adj. operating profit in FY25 Top-line & Bottom-line Results: Tobacco Segment Only Excluding Processed Food Segments;

Revenue: ¥947.2Bn (versus ¥901Bn expected) EPS: ¥109 (versus ¥92.9 expected) Starting from Q3 2025, the Pharmaceutical business is classified as discontinued operations Top-line & Bottom-line Results – Tobacco Segment Only (Excluding Pharmaceuticals and Processed Food Segments. Tobacco Segment has a 92.5% weight in revenue and 100+% weight in adjusted operating

Top-line & Bottom-line Results – Tobacco Segment Only (Excluding Pharmaceuticals and Processed Food Segments. Tobacco Segment has a 90% weight in revenue and 100+% weight in adjusted operating companies income in Q2 2025. Adjusted figures, at constant currencies) Revenue: +15.6% in Q2 2025, driven by strong pricing/mix, the inclusion of

Pharmaceutical business (including a 55% stake in Torii Pharmaceutical): Sold to Shionogi on May 7, 2025. For further details: Beyond Nicotine: Japan Tobacco Top-line & Bottom-line Results – Tobacco Segment Only (Excluding Pharmaceuticals and Processed Food Segments. Tobacco Segment has a 89% weight in revenue and 98% weight in adjusted